Last $6.82 USD
Change Today 0.00 / 0.00%
Volume 42.4K
ATNM On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 10/29/14 All times are local (Market data is delayed by at least 15 minutes).

actinium pharmaceuticals inc (ATNM) Key Developments

Actinium Announces Collaboration with Albert Einstein College of Medicine on New Actinium Program

Actinium Pharmaceuticals, Inc. announced collaboration with Albert Einstein College of Medicine on New Actinium Program. The company and Albert Einstein College of Medicine of Yeshiva University started development of an antibody construct labeled with actinium-225 using a novel technology that potentially allows for the expansion of use of the Company's proprietary platform and enables further manufacturing improvements of alpha therapy technology based drug candidates. The first antibody to be labeled using the new technology has potential to be broadly used in the field of hematology/oncology. Preclinical studies of the new technology have demonstrated significant improvements in product's manufacturing while maintaining biological integrity and properties of labeled antibodies. In addition to making the manufacturing process more time and cost efficient, the new technology allows for a greater versatility in adjusting the final constructs to various clinical situations. Clinical trials of drug candidates based on alpha emitting isotopes have already demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery.

Actinium Pharmaceuticals, Inc. - Special Call

To discuss on emerging therapies for Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. Presents at RedChip Global Online CEO Conference, Oct-15-2014 11:00 AM

Actinium Pharmaceuticals, Inc. Presents at RedChip Global Online CEO Conference, Oct-15-2014 11:00 AM.

Actinium Pharmaceuticals, Inc Appoints Richard E. Champlin to Scientific Advisory Board

Actinium Pharmaceuticals, Inc. announced the addition of Richard E. Champlin, M.D. of MD Anderson Cancer Center to its Scientific Advisory Board (SAB) for Iomab(TM)-B, the company's radioimmunotherapy asset which is preparing to enter a Phase III pivotal trial. Dr. Champlin is in his twenty-fifth year at MD Anderson Cancer Center in Houston, Texas. He holds the titles of Chair, Department of Stem Cell Transplantation and Cellular Therapy; Professor of Medicine; and Associate Division Head, Division of Cancer Medicine.

Actinium Pharmaceuticals, Inc. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 through Oct-01-2014

Actinium Pharmaceuticals, Inc. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 through Oct-01-2014. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH-4005 Basel, Switzerland. Presentation Date & Speakers: Sep-30-2014, Dragan Cicic, Chief Operating Officer and Chief Medical Officer, Sandesh C. Seth, Chairman and Member of Compensation Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATNM:US $6.82 USD 0.00

ATNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ATNM.
View Industry Companies
 

Industry Analysis

ATNM

Industry Average

Valuation ATNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 43.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTINIUM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.